Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909402 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00909402 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 39 participants.
The verdict
NCT00909402, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas.
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG BMS-833923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909402
The ClinicalTrials.gov registry entry for NCT00909402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00909402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909402 about?
NCT00909402 is a clinical study titled "A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas". The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas.
What is the current status of trial NCT00909402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2009-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00909402?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), BMS-833923 (DRUG).
Who is sponsoring clinical trial NCT00909402?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.